DENALI THERAPEUTICS INC's ticker is DNLI and the CUSIP is 24823R105. A total of 207 filers reported holding DENALI THERAPEUTICS INC in Q4 2020. The put-call ratio across all filers is 0.17 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $17,330 | +0.4% | 840 | +43.6% | 0.00% | – |
| Q2 2023 | $17,263 | +14.2% | 585 | -10.8% | 0.00% | – |
| Q1 2023 | $15,114 | +18.9% | 656 | +43.5% | 0.00% | – |
| Q4 2022 | $12,709 | -15.3% | 457 | -9.1% | 0.00% | – |
| Q3 2022 | $15,000 | +15.4% | 503 | +10.1% | 0.00% | – |
| Q2 2022 | $13,000 | -27.8% | 457 | -18.2% | 0.00% | – |
| Q1 2022 | $18,000 | -10.0% | 559 | +25.9% | 0.00% | – |
| Q4 2021 | $20,000 | -9.1% | 444 | +1.4% | 0.00% | – |
| Q3 2021 | $22,000 | -40.5% | 438 | -8.4% | 0.00% | – |
| Q2 2021 | $37,000 | +37.0% | 478 | +2.6% | 0.00% | – |
| Q1 2021 | $27,000 | -18.2% | 466 | +18.0% | 0.00% | – |
| Q4 2020 | $33,000 | +560.0% | 395 | +180.1% | 0.00% | – |
| Q3 2020 | $5,000 | +150.0% | 141 | +67.9% | 0.00% | – |
| Q2 2020 | $2,000 | – | 84 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Crestline Management, LP | 7,460,732 | $240,012,000 | 28.78% |
| Casdin Capital, LLC | 1,500,000 | $48,255,000 | 2.16% |
| Flagship Pioneering Inc. | 2,619,968 | $84,284,000 | 1.98% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 38,000 | $8,192,000 | 1.85% |
| Yiheng Capital Management, L.P. | 1,014,684 | $32,642,000 | 1.49% |
| SECTORAL ASSET MANAGEMENT INC | 207,100 | $6,662,000 | 1.18% |
| Artal Group S.A. | 600,000 | $19,302,000 | 0.81% |
| GILDER GAGNON HOWE & CO LLC | 2,619,217 | $84,260,000 | 0.78% |
| Temasek Holdings (Private) Ltd | 5,369,487 | $172,736,397 | 0.73% |
| BRANDYWINE MANAGERS, LLC | 9,601 | $309,000 | 0.53% |